The Indian central government has ordered an immediate nationwide ban on nimesulide formulations containing more than 100 mg per dose, the Ministry of Health announced. The decision, taken after consultation with the Drug Technical Advisory Board, is intended to reduce serious health risks associated with higher doses of the non-steroidal anti-inflammatory drug.
Why the nimesulide ban in India was introduced
According to the ministry, evidence indicates that consumption of nimesulide at doses above 100 mg can cause severe adverse effects, particularly on the liver. The ban has been issued under provisions of the Drugs and Cosmetics Act, 1940, and will be enforced immediately and uniformly across the country.
Health officials highlighted that nimesulide’s safety profile has been under regulatory and clinical scrutiny for many years. Several jurisdictions have already restricted or withdrawn nimesulide from the market. European countries including Finland, Spain, Ireland and Belgium moved to ban the medicine in 2007, while other regulators in Canada, Japan, the United States, Australia and the United Kingdom have imposed varying restrictions or bans.
The World Health Organization does not include nimesulide on its Model List of Essential Medicines, and national regulatory authorities have repeatedly reviewed its risk–benefit balance. Indian health experts and committees have previously limited the drug’s use in certain populations; for example, the ministry had earlier prohibited its use in children under 12 years of age.
Implications for patients and prescribers
The ministry advised patients and prescribers to switch to widely used, safer analgesics where appropriate. Medical authorities cited paracetamol and ibuprofen as effective alternatives for common pain and fever management, provided they are used at recommended doses. The Indian Council of Medical Research’s evidence supports the safety record of these alternatives when used correctly.
Pharmaceutical companies will need to modify production and distribution of affected products immediately. Regulators will oversee compliance to ensure that high-strength nimesulide formulations are withdrawn from the market and that labelling and packaging meet the new requirements.
Public health experts welcomed the move as a precautionary step to prevent drug-induced liver injury. They also urged healthcare professionals to inform patients about the change and to recommend suitable substitutes. The ministry reiterated that consumers should follow prescribed dosages and seek medical advice if they experience symptoms of liver dysfunction, such as jaundice, abdominal pain or persistent nausea.
The ban is framed as a safety-driven regulatory action rather than a punitive measure. It aligns India with several international jurisdictions that have tightened controls on nimesulide, and reflects ongoing efforts to update the country’s pharmaceutical regulatory framework in response to emerging safety data.
Authorities said they will issue further guidance to pharmacists, clinicians and manufacturers outlining compliance timelines and reporting procedures for adverse events. The government emphasised that the restriction is intended to protect public health while ensuring access to safe and effective pain-relief options.
Key Takeaways:
- India has imposed an immediate ban on nimesulide formulations exceeding 100 mg, citing health risks.
- The Ministry of Health invoked provisions of the Drugs and Cosmetics Act, 1940, after consultation with the Drug Technical Advisory Board.
- Health authorities noted liver-related safety concerns; safer alternatives such as paracetamol and ibuprofen are recommended.
- Several countries have previously restricted or banned nimesulide, and the WHO does not include it on its model list of essential medicines.
